Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8115 of 8981 results

  1. Osteoarthritis - naproxcinod [ID417]

    Discontinued Reference number: GID-TAG426

    Technology appraisal guidance
    Discontinued

  2. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued Reference number: GID-TAG408

    Technology appraisal guidance
    Discontinued

  3. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued Reference number: GID-TAG400

    Technology appraisal guidance
    Discontinued

  4. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued Reference number: GID-TAG385

    Technology appraisal guidance
    Discontinued

  5. Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

    Discontinued Reference number: GID-DT9

    Diagnostics guidance
    Discontinued

  6. Ex utero intrapartum therapy for fetal obstruction

    Discontinued Reference number: GID-IP1156

    Interventional procedures guidance
    Discontinued

  7. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

    Technology appraisal guidance
    Discontinued

  8. Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

    In development Reference number: GID-TA10667 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued Reference number: GID-TAG410

    Technology appraisal guidance
    Discontinued

  10. Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]

    Discontinued Reference number: GID-TAG413

    Technology appraisal guidance
    Discontinued

  11. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  12. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued Reference number: GID-TA10447

    Technology appraisal guidance
    Discontinued

  13. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Diabetes - buccal insulin [ID311]

    Discontinued Reference number: GID-TAG244

    Technology appraisal guidance
    Discontinued